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Rapid identiﬁcation and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and
developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for
whole-genome analysis and deciphering new mutations. The technique has been instrumental in identifying the variants of
concern (VOC) and tracking this pandemic. However, NGS is complex and expensive for large-scale adoption, and epidemiological monitoring with NGS alone could be unattainable in limited-resource settings. In this study, we explored the application of RT-qPCR-based detection of the variant identiﬁed by NGS. We analyzed a total of 78 deidentiﬁed samples that
screened positive for SARS-CoV-2 from two timeframes, August 2020 and July 2021. All 78 samples were classiﬁed into WHO
lineages by whole-genome sequencing and then compared with two commercially available RT-qPCR assays for spike protein
mutation(s). The data showed good concordance between RT-qPCR and NGS analysis for speciﬁc SARS-CoV-2 lineages and
characteristic mutations. RT-qPCR assays are quick and cost-eﬀective and thus can be implemented in synergy with NGS for
screening NGS-identiﬁed mutations of SARS-CoV-2 for clinical and epidemiological interest. Strategic use of NGS and RT-qPCR
can oﬀer several COVID-19 epidemiological advantages.

1. Introduction
The coronavirus (COVID-19) pandemic started in December 2019 in Wuhan, China. It has been considered one of
the deadliest infectious disease outbreaks in recent world
history. The causative agent of COVID-19 is the Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 is a positive-sense RNA virus belonging to the
Coronaviridae family, genus Betacoronavirus, and subgenus
sarbecovirus [1, 2]. Coronavirus has had devastating eﬀects
on the human population and to date is estimated to have

caused over 5 million deaths worldwide [3]. Rapid accurate
diagnosis of SARS-CoV-2 is the most crucial step in the
management of COVID-19—mostly achieved with reverse
transcription-quantitative polymerase chain reaction (RTqPCR). The assays detect highly conserved regions in the
open reading frame (ORF) 1a or 1b and the nucleocapsid (N)
gene of SARS-CoV-2 [4–6].
Currently, the virus continues to be a global agent of
infection. The highly mutagenic nature of SARS-CoV-2 has
assaulted many countries with second or third waves of the
outbreak [7, 8]. Mutations with higher transmissibility, a

2
more intense disease state, and that are less likely to respond
to vaccines or treatments, have been classiﬁed by the World
Health Organization (WHO) as variants of concern (VOC;
Table 1). Recent epidemiological reports released by WHO
indicated ﬁve VOCs: (1) Alpha (B.1.1.7), ﬁrst reported in the
United Kingdom (UK) in December 2020, (2) Beta (B.1.351),
ﬁrst reported in South Africa in December 2020, (3) Gamma
(P.1), ﬁrst reported in Brazil January 2021, (4) Delta
(B.1.617.2), ﬁrst reported in India December 2020, and (5)
Omicron (B.1.1.529) reported from multiple countries
(Cascella et al.) [7] Genomic changes in the receptor-binding
domain (RBD), a region of the spike protein that studs
SARS-CoV-2 to the outer cell surface, are linked to increased
capacity to strike in several outbreak phases in diﬀerent parts
of the world [9]. More recently, South Africa reported a new
SARS-CoV-2 variant to the WHO. Omicron (B.1.1.529) was
ﬁrst detected in specimens collected in Botswana. On November 26, 2021, the Technical Advisory Group on SARSCoV-2 Virus Evolution (TAG-VE) advised WHO to designate B.1.1.529 as the ﬁfth VOC [10].
There continues to be a need for swift and cost-eﬀective
SARS-CoV-2 variant detection and monitoring. Genomic
sequencing is the gold standard and most reliable method for
the detection of such changes in the viral genome. The
standard Sanger sequencing method is highly accurate but it
can only sequence a small fraction of the genome [12].
Sanger sequencing is also laborious, time-consuming, and
expensive for large-scale sequencing projects that require
rapid turnaround times. These attributes make Sanger sequencing less attractive for SARS-CoV-2 sequencing for
variant identiﬁcation and monitoring.
Targeted Next-Generation Sequencing (NGS) is also a
reliable method to identify variant strains of pathogens,
including viruses [13]. The principal advantage of NGS over
other techniques like Sanger sequencing or RT-qPCR is that
scientists and laboratorians do not require prior knowledge
of existing nucleotide sequences. Moreover, NGS has higher
discovery power and higher throughput [13]. In the current
pandemic, NGS has widely been employed to detect and
identify novel mutated viral variants of SARS-CoV-2 [14].
Although widespread adoption of NGS in clinical laboratories oﬀers eﬀective variant discovery, several challenges
impede the routine use of NGS in these settings. Besides the
need for multifaceted NGS validation studies [15], NGS
testing is complicated by the high level of necessary human
expertise and the higher cost of scalability for routine
pathogen/variant detection. Moreover, the interpretation of
results generated by NGS can be intricately complex and
their applicability to clinical decision-making is another
issue altogether. These complexities pose the need to
progress practical methodologies to identify SARS-CoV-2
mutagenic variants quickly and cost-eﬀectively.
PCR is the gold standard for the detection of preidentiﬁed genomic sequences and variations. Several RTqPCR tests were developed and commercialized very quickly
after the ﬁrst SARS-CoV-2 genome was sequenced. Technology has proven to be the most reliable tool for the diagnosis of COVID-19 and was adopted globally because of
its lower cost and complexity. Likewise, RT-qPCR can be
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deployed for mass-scale detection of a new mutation after it
is discovered by NGS. This approach has been widely
deployed in environmental surveillance of known COVID19 variants, and RT-qPCR is reported as a gold standard test
for COVID-19 surveillance in wastewater. Droplet digital
PCR (ddPCR) is a modiﬁed PCR method where ampliﬁcation is performed in submicroliter droplets, and the
number of positive droplets is enumerated for absolute
quantiﬁcation of the targets or the genomic variations.
ddPCR provides the absolute quantiﬁcation of targets and is
also reported to be more sensitive for the detection of known
SARS-CoV-2 mutations [16].
Various variant-speciﬁc RT-qPCR assays have been
developed. For example, spike protein mutation (L452R) is a
characteristic mutation of the Delta variant, and several
multiplex mutation-speciﬁc RT-qPCR assays have been
developed to detect VOCs via NGS-identiﬁed mutations.
RT-qPCR assays are widely adopted because of their lower
turnaround time (<24 hrs). Capital investment and operational cost of RT-qPCR are also signiﬁcantly cheaper than
NGS [17]. In the United States, RT-qPCR-based COVID-19
testing is reimbursed at ∼$100/sample, compared to
$300–$1000/sample for COVID-19 sequencing. NGS cost is
highly dependent on the sample volume and instrument
throughput. To achieve the lowest published cost, the laboratory has to sequence ∼30,000 samples in a single batch on
a Million Dollar instruments.
Recent advances in RT-qPCR instruments have led to
the development of smaller, cheaper, and portable instruments, and the COVID-19 pandemic has boosted the
adoption of such instrumentation. Bechtold et al. have reported the development of RT-qPCR assays for the detection
of VOCs on the basis of single nucleotide polymorphisms
(N501Y, E484K, and deletion HV69/70) in spike protein.
This assay is also validated for the ﬁeld application using a
portable peakPCR [18].
According to a technical report published by the European Centre for Disease Prevention and Control, the
WHO Regional Oﬃce for Europe-related variant detection
methods suggests NGS should perform for the conﬁrmation
of the newly emerged VOCs not for detection and prevalence calculating variants [19].
As soon as new mutations are discovered by NGS, academic and commercial researchers have rushed to design
qPCR assays for the detection of the same mutation [20].
Thermo Fisher Scientiﬁc has developed mutation-speciﬁc
assays as mutations are discovered. Several other companies
(GT Molecular, PerkinElmer, Promega, and Twist Biosciences) developed multiplex RT-qPCR panels targeting
mutations characteristic of the variant. Combinations of
such reactions are available in kit format for the detection of
known mutations deﬁning the variants. These kits are widely
used for SARS-CoV-2-variants surveillance in the environmental samples, such as wastewater [21].
We have compared the variant detection by two commercially available RT-qPCR-based solutions to whole-genome sequencing. The adoption of these kits in clinical
surveillance has been restricted because of the limited
clinical utility for individual patient variant identiﬁcation.
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RT-qPCR-based variant detection is based on limited known
mutations, compared to a whole-genome analysis by NGS
which can identify known mutations as well as discover new
mutations.
With the acknowledgment of these limitations, the
current study proposes that RT-qPCR could be utilized to
extend the mass scale detection of the mutation(s) discovered by NGS. Strategic deployment of NGS for discovering
new mutations followed by mass surveillance by RT-qPCR
could improve the epidemiological surveillance of this
pandemic. Rapid detection of known variants could also
potentially have a clinical application if future variants with
diﬀerent clinical manifestations and treatment needs are
discovered.

2. Methodology
2.1. Sample Collection. This study used 78 deidentiﬁed
sample remnants from nasopharyngeal or oropharyngeal
swabs (catalog# 202003, Nest Biotechnology Jiangsu, China)
collected from patients that screened positive for the presence of SARS-CoV-2 following RNA extraction and RTqPCR at Advanta Genetics (https://aalabs.com/) in Tyler,
Texas. All the clinical samples were collected from Texas
residents who tested positive for SARS-CoV-2 with established protocols targeting N1 and N2 genes with established
primer and probe design. Eleven samples were collected and
archived during the early (August 2020) pandemic. The
remaining 67 samples were collected in July 2021 following
the global outbreak of the Delta (B.1.617.2) variant. We
qualiﬁed the samples with moderate to high viral load by
cycle threshold (Ct) values ≤30 for N1 and N2 genes by RTqPCR testing on the LightCycler 480 System (Roche). We
also included 4 samples with low viral ampliﬁcation
(Ct � 30–35; sample 210–213) in the study to evaluate the
applicability of RT-qPCR and NGS for reduced Ct values (Ct
values are inversely proportional to ampliﬁcation thresholds;
Table 2). Written consent was obtained from the patients for
participating in the study, and only residual diagnostic
samples were used.
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2.2. RNA Extraction. Total RNA was extracted from nasopharyngeal or oropharyngeal swabs collected and transported to the lab in MANTACC Transport Medium or Viral
Transport Medium (VTM) purchased from Criterion
Clinical (https://criterionclinical.com/). RNA extraction was
carried out in a preampliﬁcation environment within a
Biosafety level 2 (BSL-2) facility using the Roche MagNA
Pure 96 System and Viral NA Small Volume Kits. Brieﬂy,
samples were lysed with 340 uL of lysis buﬀer and 10 uL of
proteinase K at 55°C for 10 minutes, followed by extraction
via the Roche MagNA Pure 96 instrument. Extracted nucleic
acids were immediately sealed with a PCR clean sealing ﬁlm
(Cat #T329-1 Simport Scientiﬁc Inc. QC J3G 4S5 Canada)
and frozen at −80°C until sequencing was imminent.
2.3. Library Preparation and Sequencing. Samples were sequenced in two laboratories using the Illumina Sequencing

3
platform, 67 samples were sequenced at Fulgent Genetic
(https://www.fulgentgenetics.com), and the remaining 21
samples were sequenced at Advanta Genetics. Sequencing
libraries were prepared using the Illumina COVIDSeq
protocol (Illumina Inc, USA). Total RNA was primed with
random hexamers, and ﬁrst-strand cDNA was synthesized
using reverse transcriptase. The SARS-CoV-2 genome was
ampliﬁed using the two sets of primers to produce amplicons
spanning the entire genome of SARS-CoV-2. The ampliﬁed
product was then processed for tagmentation and adapter
ligation using 24 IDT for Illumina Nextera UD Indexes Set
A. Further cleanup and pooling were performed as per
protocols provided by the manufacturer (Illumina Inc,
USA). A COVIDSeq positive control (Wuhan-Hu-1) and
one no template control (NTC) were processed with each
library batch. Representative libraries were quantiﬁed using
a Qubit 2.0 ﬂuorometer (Invitrogen, Inc.), and fragment
sizes were analyzed in Agilent 5200 Fragment Analyzer.
Libraries were pooled into an equimolar concentration, and
the pool was further normalized to 1nM concentration. The
ﬁnal library pool was denatured and neutralized with 0.2N
NaOH and 400 mM Tris-HCL (pH-8), respectively. Denatured libraries were further diluted to a 2 pm loading
concentration. Dual indexed paired-end sequencing with
75 bp read length was carried out using the HO ﬂow cell (150
cycles) on the Illumina MiniSeq instrument.

®

2.4. NGS Data Analysis. Illumina BaseSpace (https://
basespace.illumina.com) bioinformatics pipeline was used
for sequencing QC, FASTQ Generation, genome assembly,
and identiﬁcation of SARS-CoV-2 variants. Brieﬂy, the
Binary Base Call (BCL) raw sequencing ﬁles generated by
Illumina MiniSeq sequencing platforms were uploaded to
the Illumina BaseSpace online portal and demultiplexed to
FASTQ format using the FASTQ Generation (Version:
1.0.0.) application. The raw FASTQ ﬁles were trimmed,
sorted, and checked for quality (Q > 30) using the FASTQQC application within the BaseSpace. QC passed FASTQ
ﬁles were aligned against the SARS-CoV-2 reference genome
(NCBI RefSeq NC_045512.2) using Bio-IT Processor
(Version: 0x04261818). Then, DRAGEN COVID Lineage
(Version: 3.5.4) application in BaseSpace was used to generate a single consensus FASTA ﬁle for all the samples sequenced on a single ﬂow cell. Finally, single consensus
FASTQ was also analyzed for lineage assignment using the
web version of Phylogenetic Assignment of Named Global
Outbreak Lineages (PANGOLIN) software (https://
pangolin.cog-uk.io). Only the consensus variants identiﬁed by both applications were used for further analysis.
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2.5. Phylogenic Analysis. The FASTQ sequence ﬁle was
analyzed and visualized for evolutionary relationships
through the open-source toolkit Nextstrain (https://clades.
nextstrain.org/). GSAID database for global SARS-CoV-2
sequence analysis, available from the Nexstrain server, was
used to retrieve representative variant sequences [22]. The
NCBI databank was used to retrieve the original Wuhan
strain SARS-CoV-2 sequence. All the individual consensus
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Table 1: World Health Organization (WHO) designated variants of concern (VOC) [11].

WHO label
Pango lineage

Alpha
B.1.1.7
Δ69/70
Δ144Y
(E484K∗ )
(S494P∗ )
N501Y
A570D
D614G
P681H

Beta
B.1.351
K417N
E484K
N501Y
D614G

Gamma
P.1
K417N/T
E484K
N501Y
D614G

Classifying Mutation(s)

∗

Delta
B.1.617.2
T19R
(G142D∗ )
Δ156
Δ157
R158G
L452R
T478K
D614G
P681R
D950N

Omicron
B.1.1.529
A67V
Δ69-70
T95I
G142D
Δ143–145
Δ211
L212I
ins214EPE
G339D
S371L
S373P
S375F
K417N
N440K
G446S
S477N
T478K

E484A
Q493K
G496S
Q498R
N501Y
Y505H
T547K
D614G
H655Y
N679K
P681H
N764K
D796Y
N856K
Q954H
N969K
L981F

Detected in some sequences but not all.

genome sequence ﬁles were aligned by using the Clustal-W
multiple sequence alignment tool [23]. The phylogenetic
analysis was carried out utilizing the Clustal omega server
and the phylogenetic tree was constructed using the Mega X
tool [24] with default parameters of the maximum likelihood
method.
The further analysis aimed at investigating the conservation of spike protein in reference sequences versus clinical
strains of SARS-CoV-2 from our study using bioinformatics
tools. The protein sequences for diﬀerent ORFs were determined by either annotation by IBM Functional Genomics
Platform. [25] T-COFFEE and PRALINE software [26, 27]
were used for the alignment of spike proteins from diﬀerent
isolates and mutation position analysis (Figure 1).
2.6. COVID-19 Lineage Assignment Using RT-qPCR.
Commercially available assays from two vendors (GT
Molecular [Colorado USA], and Thermo Fisher Scientiﬁc
[Massachusetts, USA]) were evaluated for detection of
known variants, and results were compared to the NGSbased variant detection of the same samples (Table 3). Assays
from GT Molecular detected 7 spike protein mutations
(N501Y, Del69-70, E484K, K417N, K417T, L452R, and
T478K).
GT Molecular assays were provided in two diﬀerent kits
containing the variant-speciﬁc reference standard and
mutation-speciﬁc primer-probe. Ampliﬁcations are performed according to the manufacturer’s instructions in
separate master mix preparations as described in Table 3.
Brieﬂy, RNA was reverse transcribed for 10 minutes at 53°C
followed by enzyme activation for 2 minutes at 95°C, and 40
40 cycles of 15 seconds at 95°C for Denaturation and 60
seconds at 52°C for Annealing/Extension. Reactions were
performed by using qScript 1-Step Virus ToughMix
(Quantabio Inc, Beverly, MA USA) on LightCycler 480
System (Roche).

®

Two TaqMan assays from Thermo Fisher Scientiﬁc
targeting two spike protein mutations (L452R and P681R)
were performed according to the manufacturer’s instructions on LightCycler 480 System (Roche). The Delta variant
classifying mutation (L452R) was used for the ﬁnal classiﬁcation of the Delta variant across all the RT-qPCR-based
methods evaluated in this study. Whole-genome sequencing
followed PANGOLIN classiﬁcation and was used as the gold
standard for the ﬁnal variant classiﬁcation and validation of
the RT-qPCR-based variant detection methods. Unfortunately, we could not obtain the recent Omicron variant
samples to extend our investigations to this recent variant.

®

3. Results
The 78 randomly selected positive SARS-CoV-2 samples
were from two separate periods in the pandemic. NGS of the
11 samples from August 2020 revealed eight diﬀerent lineages, but none of the lineages were VOC according to the
WHO classiﬁcation (Figure 1). All samples (100% [67/67])
sequenced from July 2020 revealed the SARS-CoV-2 Delta
(B.1.617.2, AY3, and AY 25) VOC with sublineages AY.1 to
AY.3. Incidentally, the six samples concurrently sequenced
at both laboratories were identiﬁed as Delta (B.1.617.2)
VOC. Unfortunately, raw data (FASTQ ﬁles) were not
available from the samples sequenced at Fulgent Genetics.
However, the raw data from the 21 samples sequenced at
Advanta Genetics was analyzed for phylogenetic relationship and mutation discovery (Table 2). This data revealed
novel mutations belonging to existing prominent lineages
along with convergent mutations of diﬀerent lineages and
one unique mutation Figure 1.
Note. No Brazilian or United Kingdom lineages were
identiﬁed. Two groups of samples (F & D) lacked omnipresent mutation (614: D->G) which is present in most
variants of concern. Group F is of particular interest as it had
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Table 2: Data of representative samples (n � 21) sequenced and classiﬁed into Delta and non-VOC variants using NGS and RT-qPCR assays.

Sample

COVID-PCR (Ct
values)

N1
NTC

% of non-N bases
(coverage≥10x)

Median
coverage

N2

Negative Negative

665588

12.99

11.9

88.15

58

664789

28.72

27.78

99.40

221

665660

16.71

15.64

98.45

116

664822

26.3

25.24

93.87

103

666013

14.5

13.98

99.36

217

665426

15.98

14.44

98.14

128

21
22
23
24
25
26
27
28
29
210
211

21.41
25.3
25.35
28.74
19.86
17.33
20.77
19.98
26.99
33.9
32.66

21.71
26.82
25.04
29.52
20.43
17.64
21.68
20.58
27.61
32.64
31.53

100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0

1340
2380
1276
2618
229
1477
1092
1614
3734
1531
2485

212

33.19

35.37

100.0

2019

213

32.29

32.86

100.0

1888

214

25.13

25.77

100.0

2618

Wuhanhu1

25.26

25.89

100.00

3236

most of the Delta variant mutations except 614: D->G which
is present in all the samples unless otherwise marked. Group
E, on the other hand, is Delta lineage with a novel mutation
among them (i.e., 112: S->L). Group A was identical to the
Wuhan strain except for the 614: D->G mutation. Two
samples are carrying unique mutation sets: Set B had a single
sample with mutation 49: H->Y which is novel and not
found in any other lineage and Set C also had a single sample
with unreported mutation pair 54: L->F and 520: A->S.
We then turned our focus to testing the 67 Delta
(B.1.617.2) samples by using RT-qPCR methodology targeting three (L452R, T478K, and P681R) characteristic
mutations identiﬁed through sequencing. We tested each
sample using two diﬀerent commercially available (Thermo
Fisher Scientiﬁc and GT Molecular) assays and compared
the results. The Delta (B.1.617.2) classifying mutation
(L452R) was correctly identiﬁed by GT Molecular RTqPCR-based assay, and the test showed 100% concordance
for all 67 samples that were sequenced as Delta (B.1.617.2).

COVID lineage by
NGS
Next
clade
N/A
21A
(elta)
21A
(Delta)
21A
(Delta)
21A
(Delta)
21A
(Delta)
21A
(Delta)
20C
19A
20C
20A
20A
20C
20A
20C
20A
20C
20C
21A
(Delta)
21A
(Delta)
21A
(Delta)
19B

Pango

Variant-speciﬁc PCR (Ct
values)
(Thermo
(GT
ﬁsher
molecular)
scientiﬁc)

Lineage by
RT-qPCR

L452R T478K L452R P681R

N/A

Neg

Neg

Neg

Neg

N/A

AY.25

18.5

Neg

20.88

25.97

Delta

AY.3

31.81

32.6

33.97

34.37

Delta

AY.3

20.18

24.98

24.49

26.58

Delta

AY.3

20.55

Neg

22.18

24.87

Delta

B.1.617.2 22.72

33.27

27.8

28.78

Delta

AY.3

18.69

25.39

23.92

25.52

Delta

B.1.243
B.1.574
B.1.574
B.1.2
B.1
B.1.234
B.1.126
B.1.602
B.1
B.1
B.1.564

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC
Non-VOC

B.1.617.2 33.27

27.8

29.99

26.72

Delta

25.39

23.92

22.25

29.92

Delta

B.1.617.2 32.32

33.12

24.93

31.56

Delta

Neg

Neg

Neg

Non-VOC

AY.3

A

Neg

However, the Thermo Fisher Scientiﬁc assay for the same
target (L452R) did not amplify in 4 out of 67 samples
otherwise identiﬁed as Delta variant by NGS (Table 3;
Supplementary Table S1). All four samples had a relatively
low viral load (Ct > 25), with overall higher Ct values for all
the RT-qPCR assays. Considering the relatively low sensitivity of mutation-speciﬁc RT-qPCR compared to the target
detection RT-qPCR in general and the lower sensitivity of
Thermo Fisher Scientiﬁc assays, this slight discrepancy is not
alarming. Overall, the GT Molecular assay targeting the
L452R mutations had a 4.21 ± 2.3 lower Ct value when the
same RNA template was tested with both assays suggesting
higher sensitivity of the GT Molecular assay. Moreover, 5 of
67 samples were negative for T478K (GT Molecular), and
12/67 were negative for P681R speciﬁc PCR (Thermo Fisher
Scientiﬁc) using RT-qPCR (Table 3). Unfortunately, we
could not verify the absence of these mutations because NGS
data was not available for the 67 samples sequenced at
Fulgent Genetics. Thus, the L452R mutation remained the
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E

112:S->L
156:E_del
157:F_del
213
212
214
14

215

n20A
Kappa

Delta

Epsilon

15

F

Omicron

13

156:E_del
157:F_del
Abscent 614:D->G

Gamma

12

BetaV2

17

alpha
Iota

210

Eta

21
23

29

A

25

28
24
22

211

49:H->Y

B

27
54:L->F
520:A->S

216

26

Wuhan D->G
4:
61
nt
sce
Ab

D

C

Figure 1: Minimum spanning tree of the SARS-CoV-2 variants identified in samples (n  21) collected in August 2020 and July 2021.

most informative marker for RT-qPCR-based detection of
the Delta variant. All 11 samples sequenced as nonvariants of
concern were negative for all three Delta variant-specific
mutations (Table 3). Interestingly, a Beta and Gamma
variant classifying mutation (E484K) was identified (both by
RT-qPCR assays and NGS) in one sample, which is otherwise classified as a Delta variant by NGS and carries an
L452R mutation. This mutation combination should be
monitored and further investigated for its clinical
significance.
Of note, the 4 samples with lower viral amplification (30
Ct) that were included in this study were able to be characterized by NGS and both RT-qPCR assays. Two out of the
four samples were identified as Delta (B.1.617.2) variants
with the remaining two identified as non-VOC. Therefore,
NGS and RT-qPCR methodologies can potentially be used
for SARS-CoV-2 variant detection from the samples with
lower viral amplification (1000–10 copies).
In addition to NGS and RT-qPCR variant concordance
of the 78 samples, the results of this study reveal significantly
reduced diversity of SARS-CoV-2 variants from July 2020 to
August 2021. We detected 8 lineages among the 11 samples
tested from July 2020 compared to a single Delta variant
lineage with three sublineages (Delta) among 67 samples
collected in August 2021 (Figure 2). These findings are
important for understanding the evolution of SARS-CoV-2
variants in Texas (Figure 2) and support other studies
showing the predominance and infectivity of the Delta
variant [28].

4. Discussion
The emergence of new SARS-CoV-2 variants with higher
infection rates and morbidity continues to cause the global
scientific community concern. To manage further transmission and control of infection, genomic surveillance is
important for the identification and tracking of novel

variants. NGS is a very useful tool for identifying new strains
of COVID-19 and other infectious pathogens. NGS can be
used to detect novel pathogenic mutations and can also be
used to determine the rate of pathogen evolution.
Although NGS is the most reliable method for detecting
mutations in SARS-CoV-2, the methodology is not practically applicable for large-scale surveillance, particularly in
resource-limited settings. Factors like continuous validation
studies, logistic challenges, database validity, cost-benefit
analysis, and high technical expertise make the implementation of NGS in routine clinical settings difficult.
Comparatively, RT-qPCR—a gold standard for diagnosing
SARS-CoV-2—is a method that can be extended for variant
detection and monitoring in clinical settings. Although the
cost of sequencing has plummeted in the last decade, and
$1000 human genome is indeed a reality, the capital investment of the instrument (Illumina NovSeq) alone is ∼a
million USD prior to any sequencing application. COVID19 genome sequencing cost ranges from $100 to $400
(COGS [Cost of Goods] only). However, the laboratory must
batch 1000s of samples to achieve the lowest cost. The fastest
practically attainable turnaround time is ∼24 hrs for low
throughput sequencing platforms which have the highest per
sample cost. But RT-qPCR can be performed within a few
hours and per sample costs (COGS: $5-$10) are a fraction of
NGS. RT-qPCR also results in an easy-to-interpret numerical value (Ct value) compared to the complex NGS
output (FASTQ files) requiring additional resources and
time for analysis.
Accordingly, this study examined two commercially
available RT-qPCR assays for the detection of SARS-CoV-2
mutagenic variant and mutation detection and compared
the results with NGS. Both assays were able to detect L452R
mutation with 100% (67/67; GT Molecular) and 94% (63/67;
Thermo Fisher Scientific) accuracy when compared to NGS.
While NGS is an essential tool for sequencing the entire
genome and identification of new mutations, this study

Thermo ﬁsher scientiﬁc Inc., Waltham, MA, USA

GT molecular fort collins, CO, USA

Manufacturer

Reaction-1
Reaction-1
Reaction-2

A51819
A51822

Reaction - 3

Reaction-2

Reaction
Reaction-1

100172

Catalog #
100180

Targets
N501Y
Del69-70
N501Y
E484K
K417N
K417T
L452R
T478K
L452R
T478K
L452R
P681R

Variants (WHO label) harboring this mutation
Alpha (B.1.1.7), beta (B.1.351), gamma (P.1)
Alpha (UK, B.1.1.7)
Alpha (B.1.1.7), Beta (B.1.351), gamma (P.1)
Beta (B.1.351), gamma (P.1)
Beta (B.1.351), Delta plus
Gamma (P.1)
Epsilon (B.1.427/B.1.429), Delta (B.1.617.2)
Delta (B.1.617.2)
Epsilon (B.1.427/B.1.429), Delta (B.1.617.2)
Delta (B.1.617.2)
B.1.617, B.1.617.1, Delta (B.1.617.2), B.1.617.3, B.1.429
B.1.617.1, B.1.617.2, B.1.617.3

Evaluation of Q-PCR-based SARS-CoV-2 variant detection solutions

VOC
(n � 67)
PCR NGS
0
0
0
0
0
0
0
0
1
1
0
0
0
0
67
67
62
64
67
67
62
64
63
67
55
64

Non-VOC
(n � 11)
PCR NGS
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Table 3: Comparative detection of VOC classifying mutations with RT-qPCR and NGS-based approaches. ∗ Variant determined by NGS (see Appendix for method).
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August 2020 (n=11)

B.1

B.1.243

B.1.126

B.1.564

B.1.2

B.1.574

B.1.234

B.1.602

July 2021 (n=67)

Delta (B.1.617.2)
Delta (B.1.617.2.3)

Figure 2: Evolution of the SARS-CoV-2 variant in Texas over one year (August 2020 to July 2021).

suggests that RT-qPCR can aptly serve as an easy-to-deploy,
cost-effective, and time-sensitive solution for the detection
of known mutations for mass surveillance. Likewise, this
approach has been previously applied for surveillance of
leprosy and identification of zoonotic transmission in the
United States [29, 30]. The authors used NGS data to develop
an algorithm for the classification of global variants and
deployed RT-qPCR to understand the local transmission
dynamics.
The results in this study are promising because the RTqPCR lineage classification showed no mismatches when
compared with the 21 sequenced samples that had raw data.
Although these results are encouraging because of the low
cost of scalability of SARS-CoV-2 mutation detection with
RT-qPCR, other research studies using similar virus sequencing comparison methods have been less successful.
Khan and Cheung [31] noted the presence of mismatches
when comparing SARS-CoV-2 between RT-qPCR and sequencing data. Elaswad and Fawzy [32] also found this to be
the case when comparing RT-qPCR assays with available
SARS-CoV-2 genomes isolated from animals. Similarly,
Hoang et al. [33] noted missed detection with RT-qPCR
assays for influenza A (H1) when compared with sequencing. Although these studies add some concern, it does
appear strategic deployment of both NGS and RT-qPCR
technologies for the discovery and monitoring of emerging
SARS-CoV-2 mutations is likely to advance better strategies
for epidemiological characteristics.
Even though the unavailability of the raw data (FASTQ
files) from the 67 samples remains the limitation of the
study, phylogenetic analysis of the 21 samples tested at
Advanta Genetics was clustered as expected; all the VOC and
non-VOC samples were grouped appropriately. This suggests a good potential for the use of RT-qPCR approaches in
the detection of preidentified mutations and possibly application in low-cost surveillance of known variants. Importantly, this study does not suggest the RT-qPCR as a
replacement for NGS because RT-qPCR assays utilized in

this study were designed to target only a few amino acid
motifs compared to NGS, which covers a wider breadth of
the virus genome.

5. Conclusion
There are two important takeaways from this study. First, the
NGS data provided further evidence of the rapid evolution of
SARS-CoV-2 lineages including the highly transmissible
Delta variant in the East Texas region and suggests the
continued threat of COVID-19. This finding is consistent
with other research and further supports the need for rapid,
cost-effective monitoring of variant mutations. Second, the
current study endorses the potential of RT-qPCR assays as a
solution for more accessible variant monitoring. The data
showed concordance with RT-qPCR and NGS analysis for
specific SARS-CoV-2 lineages and characteristic mutations.
Thus, the deployment of RT-qPCR testing for the detection
of known SARS-CoV-2 variants may be extremely beneficial.
The key difference between the NGS and RT-qPCR is
discovery power, scalability, and throughput. Both technologies are reliable and highly sensitive. RT-qPCR can detect
only known sequences with help of specific probes and
primers. In contrast, NGS does not need prior information
about the sequence, but NGS is less cost-effective for low
target numbers and is a time-consuming method. NGS can
detect thousands of targeted regions with single-base resolution. RT-qPCR is cost-effective, and its familiar workflow
made the detection of a limited set of variants and low target
numbers easy [34]. Accordingly, is it suggested that RT-qPCR
is a quick and cost-effective alternative to sequencing for
screening known mutations of SARS-CoV-2 for clinical and
epidemiological interest, especially in developing countries
where COVID-19 diagnostic centers are limited by regional
sequencing laboratories for screening the mutations in the
SARS-CoV-2 clinical samples. The findings in this study
depict great potential for RT-qPCR to be an effective strategy
offering several epidemiological advantages.
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Appendix
A. RT-qPCR Primer and Probe Design
N1 Gene: 2019-nCoV_N1-Forward Primer—GACCCCA
AA ATCAGCGAAAT; 2019-nCoV_N1-Reverse Primer-TCT
GGTTACTGCCAGTTGAAT CTG; 2019-nCoV_N1- ProbeFAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1. N2 Ge
ne: 2019-nCoV_N2- Forward Primer- TTACAAACATT
GGCCGCAAA;
2019-nCoV_N2Reverse
Primer—GCGCGACATTCCGAAGAA; 2019-nCoV_N2-Probe- FA
M-ACAATTTGCCCCCAGCGCTTCAG-BHQ1.
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